{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T13:50:12Z","timestamp":1791726612035,"version":"4.3.4"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Cells, Molecules, and Diseases"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.bcmd.2024.102859","type":"journal-article","created":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T18:57:50Z","timestamp":1717009070000},"page":"102859","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Differential effects of iron chelators on iron burden and long-term morbidity and mortality outcomes in a large cohort of transfusion-dependent \u03b2-thalassemia patients who remained on the same monotherapy over 10\u00a0years"],"prefix":"10.1016","volume":"107","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3935-903X","authenticated-orcid":false,"given":"Khaled M.","family":"Musallam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1952-7836","authenticated-orcid":false,"given":"Susanna","family":"Barella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2346-9616","authenticated-orcid":false,"given":"Raffaella","family":"Origa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3793-5788","authenticated-orcid":false,"given":"Giovanni Battista","family":"Ferrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Lisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annamaria","family":"Pasanisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0434-0382","authenticated-orcid":false,"given":"Filomena","family":"Longo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Gianesin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9833-1016","authenticated-orcid":false,"given":"Gian Luca","family":"Forni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcmd.2024.102859_bb0005","first-page":"1157","article-title":"Quality of life and survival of patients with beta-thalassemia major","volume":"89","author":"Cao","year":"2004","journal-title":"Haematologica"},{"key":"10.1016\/j.bcmd.2024.102859_bb0010","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/S0140-6736(00)02357-6","article-title":"Survival in beta-thalassaemia major in the UK: data from the UK Thalassaemia register","volume":"355","author":"Modell","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.bcmd.2024.102859_bb0015","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJM199409013310902","article-title":"Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major","volume":"331","author":"Brittenham","year":"1994","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcmd.2024.102859_bb0020","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/1477-7525-4-73","article-title":"The impact of iron overload and its treatment on quality of life: results from a literature review","volume":"4","author":"Abetz","year":"2006","journal-title":"Health Qual. Life Outcomes"},{"key":"10.1016\/j.bcmd.2024.102859_bb0025","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/s12325-008-0085-z","article-title":"Iron chelation therapy: clinical effectiveness, economic burden and quality of life in patients with iron overload","volume":"25","author":"Payne","year":"2008","journal-title":"Adv. Ther."},{"key":"10.1016\/j.bcmd.2024.102859_bb0030","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1159\/000203853","article-title":"Results of long-term iron-chelating therapy","volume":"95","author":"Gabutti","year":"1996","journal-title":"Acta Haematol."},{"key":"10.1016\/j.bcmd.2024.102859_bb0035","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/978-1-4615-0593-8_6","article-title":"Results of long term iron chelation treatment with deferoxamine","volume":"509","author":"Davis","year":"2002","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.bcmd.2024.102859_bb0040","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1111\/j.1537-2995.2007.01416.x","article-title":"Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review","volume":"47","author":"Delea","year":"2007","journal-title":"Transfusion"},{"key":"10.1016\/j.bcmd.2024.102859_bb0045","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.clinthera.2007.05.007","article-title":"Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta-thalassemia","volume":"29","author":"Cappellini","year":"2007","journal-title":"Clin. Ther."},{"key":"10.1016\/j.bcmd.2024.102859_bb0050","doi-asserted-by":"crossref","first-page":"3455","DOI":"10.1182\/blood-2005-08-3430","article-title":"A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia","volume":"107","author":"Cappellini","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2024.102859_bb0055","doi-asserted-by":"crossref","first-page":"3738","DOI":"10.1182\/blood-2005-07-2948","article-title":"Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis","volume":"107","author":"Pennell","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2024.102859_bb0060","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1006\/bcmd.2002.0510","article-title":"Deferiprone versus deferoxamine in patients with thalassemia major: a randomized clinical trial","volume":"28","author":"Maggio","year":"2002","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.bcmd.2024.102859_bb0065","doi-asserted-by":"crossref","DOI":"10.5402\/2012\/139862","article-title":"Comparative effects of three iron chelation therapies on the quality of life of greek patients with homozygous transfusion-dependent Beta-thalassemia","volume":"2012","author":"Goulas","year":"2012","journal-title":"ISRN Hematol."},{"key":"10.1016\/j.bcmd.2024.102859_bb0070","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S0140-6736(02)09740-4","article-title":"Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia","volume":"360","author":"Anderson","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.bcmd.2024.102859_bb0075","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/0140-6736(90)92962-H","article-title":"Comparison of oral iron chelator L1 and desferrioxamine in iron-loaded patients","volume":"336","author":"Olivieri","year":"1990","journal-title":"Lancet"},{"key":"10.1016\/j.bcmd.2024.102859_bb0080","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/ajh.23876","article-title":"Sustained improvements in myocardial T2* over 2 years in severely iron-overloaded patients with beta thalassemia major treated with deferasirox or deferoxamine","volume":"90","author":"Pennell","year":"2015","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.bcmd.2024.102859_bb0085","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1182\/blood-2013-04-497842","article-title":"A 1-year randomized controlled trial of deferasirox vs deferoxamine for myocardial iron removal in beta-thalassemia major (CORDELIA)","volume":"123","author":"Pennell","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2024.102859_bb0090","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/ajh.21993","article-title":"Iron chelation adherence to deferoxamine and deferasirox in thalassemia","volume":"86","author":"Trachtenberg","year":"2011","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.bcmd.2024.102859_bb0095","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1159\/000313447","article-title":"Improved treatment satisfaction and convenience with deferasirox in iron-overloaded patients with beta-Thalassemia: Results from the ESCALATOR Trial","volume":"123","author":"Taher","year":"2010","journal-title":"Acta Haematol."},{"key":"10.1016\/j.bcmd.2024.102859_bb0100","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1034\/j.1600-0609.2001.067001030.x","article-title":"Comparison between deferoxamine and deferiprone (L1) in iron-loaded thalassemia patients","volume":"67","author":"Taher","year":"2001","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.bcmd.2024.102859_bb0105","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/jmri.22621","article-title":"Impact of magnetic resonance imaging on cardiac mortality in thalassemia major","volume":"34","author":"Chouliaras","year":"2011","journal-title":"J. Magn. Reson. Imaging"},{"key":"10.1016\/j.bcmd.2024.102859_bb0110","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/1532-429X-10-42","article-title":"Improved survival of thalassaemia major in the UK and relation to T2* cardiovascular magnetic resonance","volume":"10","author":"Modell","year":"2008","journal-title":"J. Cardiovasc. Magn. Reson."},{"key":"10.1016\/j.bcmd.2024.102859_bb0115","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1002\/ajh.26798","article-title":"Overall and complication-free survival in a large cohort of patients with beta-thalassemia major followed over 50 years","volume":"98","author":"Forni","year":"2023","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.bcmd.2024.102859_bb0120","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1002\/ajh.23715","article-title":"MRI guided iron assessment and oral chelator use improve iron status in thalassemia major patients","volume":"89","author":"Nichols-Vinueza","year":"2014","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.bcmd.2024.102859_bb0125","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1182\/blood-2011-04-344507","article-title":"Chelation use and iron burden in North American and British thalassemia patients: a report from the Thalassemia Longitudinal Cohort","volume":"119","author":"Kwiatkowski","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2024.102859_bb0130","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/ejh.13512","article-title":"Changing patterns in the epidemiology of beta-thalassemia","volume":"105","author":"Kattamis","year":"2020","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.bcmd.2024.102859_bb0135","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1111\/bjh.17091","article-title":"Co-morbidities and mortality associated with transfusion-dependent beta-thalassaemia in patients in England: a 10-year retrospective cohort analysis","volume":"191","author":"Jobanputra","year":"2020","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.bcmd.2024.102859_bb0140","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.3324\/haematol.2009.009118","article-title":"Improved survival in thalassemia major patients on switching from desferrioxamine to combined chelation therapy with desferrioxamine and deferiprone","volume":"94","author":"Telfer","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.bcmd.2024.102859_bb0145","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.bcmd.2009.01.002","article-title":"Improving survival with deferiprone treatment in patients with thalassemia major: a prospective multicenter randomised clinical trial under the auspices of the Italian Society for Thalassemia and Hemoglobinopathies","volume":"42","author":"Maggio","year":"2009","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.bcmd.2024.102859_bb0150","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s00277-018-3493-4","article-title":"National registry of hemoglobinopathies in Greece: updated demographics, current trends in affected births, and causes of mortality","volume":"98","author":"Voskaridou","year":"2019","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.bcmd.2024.102859_bb0155","first-page":"873","article-title":"Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload","volume":"91","author":"Piga","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.bcmd.2024.102859_bb0160","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1002\/ajh.25103","article-title":"The effect of iron chelation therapy on overall survival in sickle cell disease and beta-thalassemia: a systematic review","volume":"93","author":"Ballas","year":"2018","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.bcmd.2024.102859_bb0165","doi-asserted-by":"crossref","first-page":"e469","DOI":"10.1016\/S2352-3026(20)30100-9","article-title":"Evaluation of the efficacy and safety of deferiprone compared with deferasirox in paediatric patients with transfusion-dependent haemoglobinopathies (DEEP-2): a multicentre, randomised, open-label, non-inferiority, phase 3 trial","volume":"7","author":"Maggio","year":"2020","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.bcmd.2024.102859_bb0170","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1007\/s00277-012-1480-8","article-title":"Cardiac iron removal and functional cardiac improvement by different iron chelation regimens in thalassemia major patients","volume":"91","author":"Cassinerio","year":"2012","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.bcmd.2024.102859_bb0175","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3324\/haematol.2009.019042","article-title":"Deferasirox, deferiprone and desferrioxamine treatment in thalassemia major patients: cardiac iron and function comparison determined by quantitative magnetic resonance imaging","volume":"96","author":"Pepe","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.bcmd.2024.102859_bb0180","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1080\/03630269.2021.1999258","article-title":"Comparative efficacy and safety between deferiprone and deferasirox with special reference to serum ferritin level and cardiac function in Bengali beta-thalassemia major children","volume":"45","author":"Tripathy","year":"2021","journal-title":"Hemoglobin"},{"key":"10.1016\/j.bcmd.2024.102859_bb0185","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/ejh.12989","article-title":"Longitudinal changes in LIC and other parameters in patients receiving different chelation regimens: data from LICNET","volume":"100","author":"Vitrano","year":"2018","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.bcmd.2024.102859_bb0190","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1002\/ajh.23469","article-title":"Longitudinal monitoring of cardiac siderosis using cardiovascular magnetic resonance T2* in patients with thalassemia major on various chelation regimens: a 6-year study","volume":"88","author":"Ambati","year":"2013","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.bcmd.2024.102859_bb0195","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.bcmd.2013.06.001","article-title":"Longitudinal analysis of heart and liver iron in thalassemia major patients according to chelation treatment","volume":"51","author":"Danjou","year":"2013","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.bcmd.2024.102859_bb0200","series-title":"Guidelines for the Management of Transfusion Dependent Thalassaemia (TDT)","author":"Cappellini","year":"2021"},{"key":"10.1016\/j.bcmd.2024.102859_bb0205","first-page":"1187","article-title":"Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine","volume":"89","author":"Borgna-Pignatti","year":"2004","journal-title":"Haematologica"},{"key":"10.1016\/j.bcmd.2024.102859_bb0210","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1046\/j.1365-2141.2000.02298.x","article-title":"Hepatic iron concentration combined with long-term monitoring of serum ferritin to predict complications of iron overload in thalassaemia major","volume":"110","author":"Telfer","year":"2000","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.bcmd.2024.102859_bb0215","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1002\/hep.1840060106","article-title":"Value of hepatic iron measurements in early hemochromatosis and determination of the critical iron level associated with fibrosis","volume":"6","author":"Bassett","year":"1986","journal-title":"Hepatology"},{"key":"10.1016\/j.bcmd.2024.102859_bb0220","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1182\/blood.V89.3.739","article-title":"Iron-chelating therapy and the treatment of thalassemia","volume":"89","author":"Olivieri","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2024.102859_bb0225","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1182\/blood-2004-01-0177","article-title":"Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance","volume":"105","author":"St Pierre","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2024.102859_bb0230","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1182\/blood.V100.1.17","article-title":"Effects of iron overload and hepatitis C virus positivity in determining progression of liver fibrosis in thalassemia following bone marrow transplantation","volume":"100","author":"Angelucci","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2024.102859_bb0235","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1007\/s00277-020-04117-z","article-title":"Cardiac T2* MR in patients with thalassemia major: a 10-year long-term follow-up","volume":"99","author":"Daar","year":"2020","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.bcmd.2024.102859_bb0240","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1053\/euhj.2001.2822","article-title":"Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload","volume":"22","author":"Anderson","year":"2001","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.bcmd.2024.102859_bb0245","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1161\/CIRCULATIONAHA.109.874487","article-title":"Cardiac T2* magnetic resonance for prediction of cardiac complications in thalassemia major","volume":"120","author":"Kirk","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.bcmd.2024.102859_bb0250","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.3324\/haematol.2013.083634","article-title":"Myocardial Iron in thalassemia, international survey of T2* cardiovascular magnetic resonance in beta-thalassemia major","volume":"98","author":"Carpenter","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.bcmd.2024.102859_bb0255","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2011.06.065","article-title":"Improvement in liver pathology of patients with beta-thalassemia treated with deferasirox for at least 3 years","volume":"141","author":"Deugnier","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bcmd.2024.102859_bb0260","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1182\/blood-2002-01-0306","article-title":"Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent beta-thalassemia","volume":"100","author":"Wanless","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2024.102859_bb0265","doi-asserted-by":"crossref","first-page":"E172","DOI":"10.1002\/ajh.25122","article-title":"Renal safety under long-course deferasirox therapy in iron overloaded transfusion-dependent beta-thalassemia and other anemias","volume":"93","author":"Origa","year":"2018","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.bcmd.2024.102859_bb0270","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1111\/bjh.13217","article-title":"Deferasirox effect on renal haemodynamic parameters in patients with transfusion-dependent beta thalassaemia","volume":"168","author":"Piga","year":"2015","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.bcmd.2024.102859_bb0275","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1111\/bjh.12340","article-title":"Assessment and management of iron overload in beta-thalassaemia major patients during the 21st century: a real-life experience from the Italian WEBTHAL project","volume":"161","author":"Piga","year":"2013","journal-title":"Br. J. Haematol."}],"container-title":["Blood Cells, Molecules, and Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979624000378?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979624000378?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,2]],"date-time":"2024-06-02T18:54:16Z","timestamp":1717354456000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1079979624000378"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":55,"alternative-id":["S1079979624000378"],"URL":"https:\/\/doi.org\/10.1016\/j.bcmd.2024.102859","relation":{},"ISSN":["1079-9796"],"issn-type":[{"value":"1079-9796","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Differential effects of iron chelators on iron burden and long-term morbidity and mortality outcomes in a large cohort of transfusion-dependent \u03b2-thalassemia patients who remained on the same monotherapy over 10\u00a0years","name":"articletitle","label":"Article Title"},{"value":"Blood Cells, Molecules, and Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcmd.2024.102859","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102859"}}